Mizuho Says Harmony Biosciences Files New Patent Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy HRMY?
Mizuho analyst Graig Suvannavejh says the firm has learned of a new patent lawsuit filed by Harmony Biosciences against AET Pharma, the sole remaining generic challenger that has yet to settle. Harmony's new lawsuit alleges infringement of a patent covering an amorphous formulation of pitolisant, which was recently licensed by Harmony, the analyst tells investors in a research note. Mizuho now believes Harmony's Wakix franchise should be viewed as "protected and fully intact" until 2030. The firm views the lawsuit as a "significant development" and "major positive" for the company. It should help remove a "major stock overhang" stemming from concerns around a generic coming well before 2030, contends Mizuho. The firm reiterates a an Outperform rating on the shares with a $50 price target.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HRMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HRMY
Wall Street analysts forecast HRMY stock price to rise
6 Analyst Rating
5 Buy
0 Hold
1 Sell
Moderate Buy
Current: 32.080
Low
32.00
Averages
43.83
High
55.00
Current: 32.080
Low
32.00
Averages
43.83
High
55.00
About HRMY
Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Harmony Biosciences Shares Rise on Patent Litigation News
- Patent Litigation Update: Harmony Biosciences filed a patent infringement lawsuit on April 20 against AET Pharma and its partner Sandoz regarding the '920 patent for Wakix, its only approved product, indicating a proactive stance against generics and likely preventing market entry before 2030.
- Analyst Optimism: Mizuho analyst Graig Suvannavejh described the lawsuit as a “significant positive” for Harmony, asserting that the Wakix franchise is now protected, reiterating an Outperform rating with a $50 price target, reflecting confidence in the company's growth trajectory.
- Revenue Forecast Increase: Harmony anticipates Wakix revenues to range between $1 billion and $1.04 billion in 2026, highlighting strong market demand in the sleep disorder treatment sector, while also expanding its late-stage CNS pipeline, enhancing future growth potential.
- Financial Performance: Harmony reported a non-GAAP EPS of $0.57, missing expectations by $0.50, yet revenue of $243.78 million exceeded forecasts by $3.46 million, indicating resilience in revenue growth despite profitability pressures.
See More
Harmony Biosciences Sues AET Pharma Over Patent Infringement
- Patent Lawsuit Development: Harmony Biosciences has filed a lawsuit against AET Pharma for allegedly infringing a patent covering pitolisant, a move viewed by Mizuho as a significant positive for the company, expected to protect its Wakix franchise through 2030.
- Stock Price Surge: Following the announcement of the new lawsuit by Mizuho analysts, Harmony's shares soared over 18% in Tuesday's trading, reflecting optimistic market sentiment and increased investor confidence in the company's patent protections.
- Analyst Rating Upgrade: Mizuho reiterated its ‘Outperform’ rating on Harmony, setting a price target of $50, implying a potential upside of about 50% from current levels, further solidifying market expectations for the company's future growth.
- Positive Market Sentiment: According to Stocktwits data, retail sentiment around Harmony is trending bullish with high message volume, indicating investor optimism regarding the company's potential in treating narcolepsy and related conditions.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, reflecting the latest market perspectives on these stocks, which could influence investor decisions and market trends.
- Overview of Rating Changes: While specific upgrades and downgrades are not detailed, the overall rating changes may lead to short-term volatility in related stocks, prompting investors to stay alert.
- Expected Market Reaction: Analyst rating adjustments typically attract market attention, potentially affecting investor confidence and trading volumes, thereby impacting stock prices.
- Impact on Investor Decisions: Investors considering buying CAVA stock should pay attention to analysts' views to make more informed investment decisions, even though specific recommendations are not provided in this article.
See More
Harmony Biosciences Q4 2025 Earnings Highlights
- Significant Revenue Growth: In Q4 2025, Harmony Biosciences reported net product revenue of $243.8 million, a 21% increase from $201.3 million in the same quarter last year, indicating strong demand in the narcolepsy market and sustained profitability.
- Sustained Patient Growth: CEO Jeffrey Dayno highlighted that the fourth quarter saw an average addition of over 400 patients, marking the first time in franchise history, showcasing WAKIX's unique competitive advantage and future growth potential.
- Robust Cash Flow: As of the end of Q4, the company had $882.5 million in cash, cash equivalents, and investments, ensuring funding for future R&D and market expansion, thereby enhancing financial flexibility within the industry.
- Optimistic Outlook: Management reiterated guidance for WAKIX net revenue of $1 billion to $1.04 billion in 2026, reflecting strong confidence in the narcolepsy market and the brand's blockbuster potential.
See More
Harmony Biosciences Q4 Earnings Analysis
- Earnings Performance: Harmony Biosciences reported a Q4 Non-GAAP EPS of $0.57, missing expectations by $0.50, indicating profitability challenges that could negatively impact investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $243.78 million, a 21.1% year-over-year increase, beating market expectations by $3.46 million, suggesting sustained product demand that may lay a foundation for future performance.
- Patient Growth: The average number of patients on WAKIX increased by approximately 400 to around 8,500 in Q4, marking the third consecutive quarter of over 400 new patients, demonstrating the product's market acceptance and growth potential.
- Future Guidance: Harmony reiterated its 2026 net revenue guidance for WAKIX at $1.0 to $1.04 billion, and despite the current earnings miss, the company's confidence in future revenues may attract long-term investor interest.
See More
Harmony Biosciences Reports $868.5 Million Revenue for 2025, Guidance for 2026 Exceeds $1 Billion
- Significant Revenue Growth: Harmony Biosciences reported net product revenue of $868.5 million for 2025, reflecting a 22% year-over-year increase, driven by sustained demand for WAKIX among approximately 80,000 diagnosed narcolepsy patients, reinforcing the company's profitability and market position in the biotech sector.
- Optimistic Future Outlook: The company reiterated its 2026 WAKIX net revenue guidance of $1.0 to $1.04 billion, indicating a trajectory towards blockbuster status, showcasing the strong market potential and ongoing momentum of the Pitolisant franchise.
- Increased R&D Investment: Research and development expenses reached $49.9 million in Q4 2025, a 44% increase, demonstrating the company's commitment to advancing new drug development and expanding its product pipeline, particularly in the field of central nervous system disorders.
- Market Expansion Strategy: Harmony plans to broaden the indications for Pitolisant into larger CNS conditions, which is expected to provide new revenue growth drivers in the future, especially in the management of fatigue, thereby enhancing its competitive edge in the market.
See More
Harmony Biosciences Shares Rise on Patent Litigation News
- Patent Litigation Update: Harmony Biosciences filed a patent infringement lawsuit on April 20 against AET Pharma and its partner Sandoz regarding the '920 patent for Wakix, its only approved product, indicating a proactive stance against generics and likely preventing market entry before 2030.
- Analyst Optimism: Mizuho analyst Graig Suvannavejh described the lawsuit as a “significant positive” for Harmony, asserting that the Wakix franchise is now protected, reiterating an Outperform rating with a $50 price target, reflecting confidence in the company's growth trajectory.
- Revenue Forecast Increase: Harmony anticipates Wakix revenues to range between $1 billion and $1.04 billion in 2026, highlighting strong market demand in the sleep disorder treatment sector, while also expanding its late-stage CNS pipeline, enhancing future growth potential.
- Financial Performance: Harmony reported a non-GAAP EPS of $0.57, missing expectations by $0.50, yet revenue of $243.78 million exceeded forecasts by $3.46 million, indicating resilience in revenue growth despite profitability pressures.
See More
Harmony Biosciences Sues AET Pharma Over Patent Infringement
- Patent Lawsuit Development: Harmony Biosciences has filed a lawsuit against AET Pharma for allegedly infringing a patent covering pitolisant, a move viewed by Mizuho as a significant positive for the company, expected to protect its Wakix franchise through 2030.
- Stock Price Surge: Following the announcement of the new lawsuit by Mizuho analysts, Harmony's shares soared over 18% in Tuesday's trading, reflecting optimistic market sentiment and increased investor confidence in the company's patent protections.
- Analyst Rating Upgrade: Mizuho reiterated its ‘Outperform’ rating on Harmony, setting a price target of $50, implying a potential upside of about 50% from current levels, further solidifying market expectations for the company's future growth.
- Positive Market Sentiment: According to Stocktwits data, retail sentiment around Harmony is trending bullish with high message volume, indicating investor optimism regarding the company's potential in treating narcolepsy and related conditions.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, reflecting the latest market perspectives on these stocks, which could influence investor decisions and market trends.
- Overview of Rating Changes: While specific upgrades and downgrades are not detailed, the overall rating changes may lead to short-term volatility in related stocks, prompting investors to stay alert.
- Expected Market Reaction: Analyst rating adjustments typically attract market attention, potentially affecting investor confidence and trading volumes, thereby impacting stock prices.
- Impact on Investor Decisions: Investors considering buying CAVA stock should pay attention to analysts' views to make more informed investment decisions, even though specific recommendations are not provided in this article.
See More
Harmony Biosciences Q4 2025 Earnings Highlights
- Significant Revenue Growth: In Q4 2025, Harmony Biosciences reported net product revenue of $243.8 million, a 21% increase from $201.3 million in the same quarter last year, indicating strong demand in the narcolepsy market and sustained profitability.
- Sustained Patient Growth: CEO Jeffrey Dayno highlighted that the fourth quarter saw an average addition of over 400 patients, marking the first time in franchise history, showcasing WAKIX's unique competitive advantage and future growth potential.
- Robust Cash Flow: As of the end of Q4, the company had $882.5 million in cash, cash equivalents, and investments, ensuring funding for future R&D and market expansion, thereby enhancing financial flexibility within the industry.
- Optimistic Outlook: Management reiterated guidance for WAKIX net revenue of $1 billion to $1.04 billion in 2026, reflecting strong confidence in the narcolepsy market and the brand's blockbuster potential.
See More
Harmony Biosciences Q4 Earnings Analysis
- Earnings Performance: Harmony Biosciences reported a Q4 Non-GAAP EPS of $0.57, missing expectations by $0.50, indicating profitability challenges that could negatively impact investor confidence.
- Revenue Growth: The company achieved Q4 revenue of $243.78 million, a 21.1% year-over-year increase, beating market expectations by $3.46 million, suggesting sustained product demand that may lay a foundation for future performance.
- Patient Growth: The average number of patients on WAKIX increased by approximately 400 to around 8,500 in Q4, marking the third consecutive quarter of over 400 new patients, demonstrating the product's market acceptance and growth potential.
- Future Guidance: Harmony reiterated its 2026 net revenue guidance for WAKIX at $1.0 to $1.04 billion, and despite the current earnings miss, the company's confidence in future revenues may attract long-term investor interest.
See More
Harmony Biosciences Reports $868.5 Million Revenue for 2025, Guidance for 2026 Exceeds $1 Billion
- Significant Revenue Growth: Harmony Biosciences reported net product revenue of $868.5 million for 2025, reflecting a 22% year-over-year increase, driven by sustained demand for WAKIX among approximately 80,000 diagnosed narcolepsy patients, reinforcing the company's profitability and market position in the biotech sector.
- Optimistic Future Outlook: The company reiterated its 2026 WAKIX net revenue guidance of $1.0 to $1.04 billion, indicating a trajectory towards blockbuster status, showcasing the strong market potential and ongoing momentum of the Pitolisant franchise.
- Increased R&D Investment: Research and development expenses reached $49.9 million in Q4 2025, a 44% increase, demonstrating the company's commitment to advancing new drug development and expanding its product pipeline, particularly in the field of central nervous system disorders.
- Market Expansion Strategy: Harmony plans to broaden the indications for Pitolisant into larger CNS conditions, which is expected to provide new revenue growth drivers in the future, especially in the management of fatigue, thereby enhancing its competitive edge in the market.
See More
